A rich R&D pipeline of second-wave DAAs could build on that achievement, with even more impressive efficacy, shorter treatment durations and better coverage of all hepatitis C genotypes.

AbbVie’s Maviret (glecaprevir+pibrentasvir) and Gilead’s Vosevi (sofosbuvir+velpatasvir+voxilepravir) cover all six major hepatitis C genotypes. In patients without cirrhosis, Maviret also ...

Before starting treatment, you need to take a simple blood test to learn which genotype you have. Some DAAs can be used to treat all hepatitis C genotypes. Effective direct-acting antiviral or 'DAA' ...